Breakthrough of solid tumor treatment: CAR-NK immunotherapy

Wenkang Wang(First Affiliated Hospital of Zhengzhou University), Yang Liu(Zhengzhou University), Zhen He(Zhengzhou University), Lifeng Li(First Affiliated Hospital of Zhengzhou University), Senbo Liu(First Affiliated Hospital of Zhengzhou University), Mingqiang Jiang(First Affiliated Hospital of Zhengzhou University), Bing Zhao(First Affiliated Hospital of Zhengzhou University), Meng Deng(First Affiliated Hospital of Zhengzhou University), Wendong Wang(First Affiliated Hospital of Zhengzhou University), Xuefang Mi(First Affiliated Hospital of Zhengzhou University), Zhenqiang Sun(First Affiliated Hospital of Zhengzhou University), Xin Ge(First Affiliated Hospital of Zhengzhou University)
Cell Death Discovery
January 20, 2024
Cited by 142Open Access
Full Text

Abstract

As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has received increasing attention in recent years, and its safety and high efficiency have irreplaceable advantages over CAR-T. Current research focuses on the application of CAR-NK in hematological tumors, while there are fewer studies on solid tumor. This article reviews the process of constructing CAR-NK, the effects of hypoxia and metabolic factors, NK cell surface receptors, cytokines, and exosomes on the efficacy of CAR-NK in solid tumor, and the role of CAR-NK in various solid tumor. The mechanism of action and the research status of the potential of CAR-NK in the treatment of solid tumor in clinical practice, and put forward the advantages, limitations and future problems of CAR-NK in the treatment of solid tumor.


Related Papers